# ASLAN PHARMACEUTICALS LT ADR (ASLN)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ASLN/

- Reporting holders: 1
- Reported value: $17
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [RHUMBLINE ADVISERS](https://holderbook.com/funds/1115418-rhumbline-advisers/) | $17 | 29 | 0.0% | 8 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 1 | $17 |
| Q1 2026 | 1 | $17 |
| Q4 2025 | 1 | $17 |
| Q3 2025 | 1 | $17 |
| Q2 2025 | 1 | $60 |
| Q1 2025 | 1 | $95 |
| Q4 2024 | 1 | $95 |
| Q3 2024 | 1 | $95 |
| Q2 2024 | 18 | $895.5K |
| Q1 2024 | 21 | $1.9M |
| Q4 2023 | 20 | $1.8M |
| Q3 2023 | 18 | $10.5M |